NeuroHealing Pharmaceuticals announces IND submission for NH001 to improve the outcome of patients in a vegetative state following a traumatic brain injury
Newton, Mass., August 31, 2005 — E-Worldwire NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announced today the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial with NH001. The study is entitled “A Double-Blind,…